These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 31742915)

  • 61. FDA implementation of standards developed by the International Conference on Harmonisation.
    Booth PM
    Food Drug Law J; 1997; 52(2):203-23. PubMed ID: 10557561
    [No Abstract]   [Full Text] [Related]  

  • 62. Human and veterinary drugs: good manufacturing practices and proposed exemptions for certain OTC products.
    Fed Regist; 1978 Sep; 43(190 Pt 2):45013-89. PubMed ID: 10316700
    [No Abstract]   [Full Text] [Related]  

  • 63. Pharmaceutical regulations in the 1980s--predictions.
    Halperin JA
    Drug Intell Clin Pharm; 1982 Apr; 16(4):320-4. PubMed ID: 7040027
    [No Abstract]   [Full Text] [Related]  

  • 64. The responsibility of FDA to the livestock industry and the consumer. II. Considerations for conducting investigational studies with food-producing animals.
    Graber G; Thomas MC
    J Anim Sci; 1973 Jul; 37(1):215-6. PubMed ID: 4720860
    [No Abstract]   [Full Text] [Related]  

  • 65. Clinical investigation of new drugs.
    N Engl J Med; 1967 Nov; 277(21):1148-9. PubMed ID: 4861565
    [No Abstract]   [Full Text] [Related]  

  • 66. OTC's: end the dual standard.
    Feldmann EG
    J Pharm Sci; 1973 Apr; 62(4):I. PubMed ID: 4699002
    [No Abstract]   [Full Text] [Related]  

  • 67. New term will distinguish tablets known to split in half.
    Thompson CA
    Am J Health Syst Pharm; 2012 Oct; 69(19):1619-21. PubMed ID: 22997111
    [No Abstract]   [Full Text] [Related]  

  • 68. Counterfeit drugs: an Australian perspective.
    Hensey CC; Gwee A
    Med J Aust; 2016 May; 204(9):344. PubMed ID: 27169964
    [No Abstract]   [Full Text] [Related]  

  • 69. Dying to live.
    Nat Med; 2006 Jun; 12(6):593. PubMed ID: 16760985
    [No Abstract]   [Full Text] [Related]  

  • 70. Pharmacokinetic drug interaction studies must consider pharmacological heterogeneity, use of repeated dosing, and translation into a message understandable to practicing clinicians.
    de Leon J; Spina E; Diaz FJ
    J Clin Psychopharmacol; 2009 Jun; 29(3):201-5. PubMed ID: 19440070
    [No Abstract]   [Full Text] [Related]  

  • 71. Counterfeit anti-infective drugs.
    Newton PN; Green MD; Fernández FM; Day NP; White NJ
    Lancet Infect Dis; 2006 Sep; 6(9):602-13. PubMed ID: 16931411
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Regulatory guidelines for biosimilars in Malaysia.
    Abas A
    Biologicals; 2011 Sep; 39(5):339-42. PubMed ID: 21784655
    [TBL] [Abstract][Full Text] [Related]  

  • 73. US drug shortages are set to reach record high in 2011, report says.
    Tanne JH
    BMJ; 2011 Dec; 343():d8307. PubMed ID: 22194406
    [No Abstract]   [Full Text] [Related]  

  • 74. Curbing counterfeit drugs.
    FDA Consum; 2006; 40(5):11. PubMed ID: 17326307
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Enforcement of the current good manufacturing practices for solid oral dosage forms after United States v. Barr Laboratories.
    Jimenez FA
    Food Drug Law J; 1997; 52(1):67-82. PubMed ID: 10346711
    [No Abstract]   [Full Text] [Related]  

  • 76. [Theoretical and practical aspects of statistic sampling and related norms of acceptance].
    Mattei A; Pietra E
    Boll Chim Farm; 1968 May; 107(5):287-95. PubMed ID: 5721540
    [No Abstract]   [Full Text] [Related]  

  • 77. The Food and Drug Administration's over-the-counter drug review: why review OTC drugs?
    Moxley JH; Yingling GL; Edwards CC
    Fed Proc; 1973 Apr; 32(4):1435-7. PubMed ID: 4701750
    [No Abstract]   [Full Text] [Related]  

  • 78. New recommendations to modernize drug manufacturing.
    FDA Consum; 2007; 41(1):4. PubMed ID: 17354283
    [No Abstract]   [Full Text] [Related]  

  • 79. Another nail in the biosimilar coffin?
    Nat Biotechnol; 2012 Mar; 30(3):198. PubMed ID: 22398594
    [No Abstract]   [Full Text] [Related]  

  • 80. Leveraging prior quantitative knowledge to guide drug development decisions and regulatory science recommendations: impact of FDA pharmacometrics during 2004-2006.
    Wang Y; Bhattaram AV; Jadhav PR; Lesko LJ; Madabushi R; Powell JR; Qiu W; Sun H; Yim DS; Zheng JJ; Gobburu JV
    J Clin Pharmacol; 2008 Feb; 48(2):146-56. PubMed ID: 18199891
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.